BioSpace News Archive

Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of Lisa Danzig, M.D., as Chief Medical Officer.

Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call on Thursday, August 5, 2021 at 4:30 p.m. Eastern time to discuss the financial results for the second quarter of 2021.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2021 financial results after the U.S. financial markets close on Thursday, August 5, 2021.

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced two oral presentations of oral ibrexafungerp from its Phase 3 VANISH Program at the Infectious Diseases Society for Obstetrics & Gynecology (IDSOG) 2021 Virtual Annual Meeting, held on July 29 and July 30, 2021

Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed potent in vitro activity against the SARS-CoV-2 Delta (India/B.1.617.2) and Gamma (Brazil/P.1) variants.

CryoLife, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that it has completed the sale of its PerClot product line to a subsidiary of Baxter International, Inc., for up to $60.8 million in cash.

I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, announced that its Board of Directors has authorized a new stock repurchase program.

Sapience Therapeutics, Inc., announced today that it has commenced dosing in the final dose-escalation cohort of an ongoing Phase 1-2 study of its lead program, ST101, for the treatment of patients with advanced and metastatic solid tumors.

Two new publications in respected medical journals further examine the importance of high-flux dialyzers in maintaining serum albumin levels in hemodialysis patients, Fresenius Medical Care North America (FMCNA) announced today.

Microbion Corporation of Bozeman, MT, announced that Mr. Robert A. Gillam, CFA, will be joining Microbion’s Board of Directors as Chairman, replacing Mr. Karim Lalji in the Board Chairman role effective immediately.